MYD88 and diffuse large B-cell lymphoma: Gain-of-function CD79 and MyD88 mutations hyper-activate BCR/TLR9 signaling in several types of lymphoma, including the diffuse large B-cell lymphoma (DLBCL) MCD subtype19–21.